Platelet specialists Dr Natalia Dovlatova, Ann White and Bob Humphries announce the launch of their new company – ‘Platelet Services Limited’, which will be based in BioCity Nottingham, UK. Collectively, the team has decades of experience in the application of platelet function testing to drug discovery and development, both preclinically and in support of clinical investigations.
Platelet Services is a contract research organisation offering standard and customised platelet testing assays to determine the effect of compounds, or other agents, on platelet function. The company can support drug discovery and development teams either by assessing the activity and potency of agents from anti-platelet projects, or ruling out possible platelet-related side-effects in other projects. Through the specialist assays offered by Platelet Services, drug discovery companies will be able to better understand the effect of their candidate compounds on platelet function. There is an increasing need for such studies as new targets are explored in areas such as proliferative diseases and in understanding the potential bleeding or thrombotic risk that may be associated with emerging drug combinations.
The Platelet Services team was a key part of the Thrombosis and Haemostasis Research Group at the University of Nottingham, and then its spin-out company, Platelet Solutions, before forming a dedicated CRO for platelet function testing. “We have a team of expert platelet scientists to advance our new venture. Platelet Services is one of the very few global CROs specialising in platelet function testing for the drug discovery sector, so we are very excited about all the opportunities ahead of us”, says Dr. Natalia Dovlatova, co-founder and CEO, Platelet Services.
Platelet Services Ltd., BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF email@example.com